Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10336722 Tetrahydroquinoline compositions as BET bromodomain inhibitors

Patent 10336722 was granted and assigned to FORMA Therapeutics on July, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
FORMA Therapeutics
FORMA Therapeutics
Date Filed
March 27, 2018
Date of Patent
July 2, 2019
Patent Applicant
FORMA Therapeutics
FORMA Therapeutics
Patent Application Number
15937271
Patent Citations Received
‌
US Patent 10611750 Tetrahydroquinoline compositions as bet bromodomain inhibitors
0
‌
US Patent 10703764 Benzopiperazine compositions as BET bromodomain inhibitors
‌
US Patent 10793561 1,8-naphthyridinone compounds and uses thereof
0
‌
US Patent 11584756 Heterocyclic compounds as BET inhibitors
0
‌
US Patent 11028058 Heterocyclic compounds as adenosine antagonists
‌
US Patent 11254670 1,8-naphthyridinone compounds and uses thereof
‌
US Patent 11306071 Heterocyclic compounds as adenosine antagonists
‌
US Patent 11801243 Bromodomain inhibitors for androgen receptor-driven cancers
Patent Inventor Names
Adam C. Talbot
0
David S. Millan
0
George P. Luke
0
Matthew W. Martin
0
Shawn E. R. Schiller
0
Torsten Herbertz
0
Goss S. Kauffman
0
Katherine J. Kayser-Bricker
0
Kenneth W. Bair
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10336722
Patent Primary Examiner
‌
D Margaret M Seaman

Find more entities like US Patent 10336722 Tetrahydroquinoline compositions as BET bromodomain inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.